Back to RA CAPITAL MANAGEMENT, L.P.

FDMT
Showing 8 of 12 quarters

Position history for RA CAPITAL MANAGEMENT, L.P.'s holdings in 4D MOLECULAR THERAPEUTICS IN

RA CAPITAL MANAGEMENT, L.P. holds 5M shares of FDMT (4D MOLECULAR THERAPEUTICS IN), worth $47M as of 2026-Q1. The position was decreased (-10.7% shares). FDMT represents 0.5% of RA CAPITAL MANAGEMENT, L.P.'s portfolio.

Current Value

$47M

Current Shares

5M

Total Value Change

-$60M

Total Shares Change

-48,432

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Decreased
5M
-10.7%
$47M0.5%$8.46
0
2025-Q4
Increased
5.7M
+23.9%
$42.4M0.4%$7.58
42
2025-Q3
Unchanged
4.6M
0.0%
$39.7M0.5%$8.35
0
2025-Q2
Unchanged
4.6M
0.0%
$16.9M0.3%$3.84
0
2025-Q1
Unchanged
4.6M
0.0%
$14.7M0.2%$3.63
0
2024-Q4
Decreased
4.6M
-10.5%
$25.4M0.3%$5.30
0
2024-Q3
Unchanged
5.1M
0.0%
$55.1M0.6%$10.83
0
2024-Q2
Increased
5.1M
+0.9%
$107M1.4%$20.99
48

Other major holders of FDMT: VIKING GLOBAL INVESTORS LP, BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used